The Biden administration has proposed a new plan to expand coverage of glucagon-like peptide-1 (GLP-1) medications such ...
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...
Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...
Health and Me on MSN7h
When Ozempic And Wegovy Fail To Work- Why GLP-1 Drugs Aren’t The Magic Bullet For EveryoneWhen Ozempic and Wegovy don’t work, genetic differences, medical conditions, or side effects could be to blame. Is it normal, ...
The Centers for Medicare and Medicaid Services draft regulation also would introduce Medicare and Medicaid coverage of ...
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and ...
In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...
Those on the medications, known as GLP-1s or glucagon-like peptide-1, will additionally weigh in four times a month on ...
News Medical on MSN6d
Impact of glucagon-like peptide-1 receptor agonists on alcohol consumptionThe impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback